True North scouts for acquisitions in orthopaedics and gynaecology space

Now, True North is focussed on growing Integrace by buying other products, divisions or smaller companies. Integrace is clocking a 12-15 per cent growth

Homegrown private equity (PE) player True North is scouting for acquisitions in the orthopaedics and gynaecology space to build its domestic formulations portfolio. The PE operates in this space through its portfolio company Integrace. 

The PE firm is open to having co-investors, including other PE firms, to fund future acquisitions by Integrace. “In the last four-five years, we have been eyeing pharma as an area of opportunity and we are looking at several other segments – from contract manufacturing to active pharmaceutical ingredients, biosimilars and also domestic formulations,” said Satish Chander, partner, True North. 

True North wanted to have a platform in